Ieq Capital LLC Purchases 14,015 Shares of Eli Lilly and Company $LLY

Key Points

• Ieq Capital LLC increased its stake in Eli Lilly and Company by 21% during the first quarter, owning 80,799 shares worth approximately $66.73 million.
• Insider transactions revealed that both EVP Daniel Skovronsky and CEO David A. Ricks purchased shares on August 12, boosting their holdings significantly.
• The company reported a strong earnings growth, posting $6.31 EPS, exceeding analysts' expectations, and set a guidance for FY 2025 of 21.75-23.00 EPS.

Ieq Capital LLC boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 21.0% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 80,799 shares of the company's stock after acquiring an additional 14,015 shares during the period. Ieq Capital LLC's holdings in Eli Lilly and Company were worth $66,734,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in LLY. Brighton Jones LLC grew its position in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its position in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after purchasing an additional 40 shares in the last quarter. Orion Capital Management LLC grew its position in shares of Eli Lilly and Company by 2.5% in the fourth quarter. Orion Capital Management LLC now owns 1,610 shares of the company's stock valued at $1,243,000 after purchasing an additional 40 shares in the last quarter. Bank Pictet & Cie Europe AG grew its position in shares of Eli Lilly and Company by 4.1% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company's stock valued at $49,993,000 after purchasing an additional 2,568 shares in the last quarter. Finally, Breed s Hill Capital LLC boosted its holdings in Eli Lilly and Company by 212.0% in the 4th quarter. Breed s Hill Capital LLC now owns 1,426 shares of the company's stock valued at $1,101,000 after purchasing an additional 969 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

LLY traded up $0.45 on Friday, reaching $732.41. The company had a trading volume of 2,548,350 shares, compared to its average volume of 6,895,566. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market cap of $693.20 billion, a price-to-earnings ratio of 47.87, a P/E/G ratio of 1.02 and a beta of 0.44. The business has a 50 day simple moving average of $748.68 and a 200 day simple moving average of $785.49. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $969.65.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company's revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson purchased 200 shares of the business's stock in a transaction on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Daniel Skovronsky purchased 1,000 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were acquired at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares of the company's stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have commented on LLY. Morgan Stanley reissued an "overweight" rating and issued a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Wall Street Zen raised shares of Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a report on Saturday. HSBC raised shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and raised their price target for the company from $675.00 to $700.00 in a report on Wednesday. UBS Group cut their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. Finally, Daiwa America downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average price target of $950.17.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.